Asset Details
Do you wish to reserve the book?
In vivo pharmacokinetics of ginsenoside compound K mediated by gut microbiota
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
In vivo pharmacokinetics of ginsenoside compound K mediated by gut microbiota
Do you wish to request the book?
In vivo pharmacokinetics of ginsenoside compound K mediated by gut microbiota
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
In vivo pharmacokinetics of ginsenoside compound K mediated by gut microbiota
2024
Overview
Ginsenoside Compound K (GCK) is the main metabolite of natural protopanaxadiol ginsenosides with diverse pharmacological effects. Gut microbiota contributes to the biotransformation of GCK, while the effect of gut microbiota on the pharmacokinetics of GCK
in vivo
remains unclear. To illustrate the role of gut microbiota in GCK metabolism
in vivo
, a systematic investigation of the pharmacokinetics of GCK in specific pathogen free (SPF) and pseudo-germ-free (pseudo-GF) rats were conducted. Pseudo-GF rats were treated with non-absorbable antibiotics. Liquid chromatography tandem mass spectrometry (LC–MS/MS) was validated for the quantification of GCK in rat plasma. Compared with SPF rats, the plasma concentration of GCK significantly increased after the gut microbiota depleted. The results showed that GCK absorption slowed down, T
max
delayed by 3.5 h, AUC
0-11
increased by 1.3 times, CL
z/F
decreased by 0.6 times in pseudo-GF rats, and C
max
was 1.6 times higher than that of normal rats. The data indicated that gut microbiota played an important role in the pharmacokinetics of GCK
in vivo
.
Publisher
Public Library of Science,Public Library of Science (PLoS)
